On August 13, 2024, X4 Pharmaceuticals received a letter from Nasdaq stating that its stock price has been below the required $1.00 for 32 consecutive business days, but it has been granted an additional 180 days until August 11, 2025, to regain compliance, possibly through a reverse stock split.